Investment bank Goldman Sachs is investing $100 million in the Israeli company Mobileye. This reflects a valuation of $600 million.
Hebrew University and the technology transfer company Yissum announced on Wednesday that formation of a new consortium to develop water technology, the first such project in Israel.
The consortium has been awarded an operational budget for three years by the chief scientist's office in the Industry, Trade and Labor Ministry, with funding for the first year standing at NIS 15 million.
According to consortium representatives, the group hopes to find effective solutions to battle biofouling and also to develop new and useful methods to treat and save water.
The treatment was found in testing to have eliminated four different types of allergic diseases in mice.
Protalix BioTherapeutics, Inc. , today announced it has signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel, and the Boyce Thompson Institute for Plant Research, at Cornell University, Ithaca, New York, to develop a proprietary plant cell-based acetylcholinestrase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, including a biodefense program.
Neocrine Biosciences Inc. will develop valnoctamide, which has potential for treating neurological and psychiatric disorders discovered at Hebrew University.
Prof. Naftali Tishby dreams of the day when we will be able transfer a copy of our souls onto the computer before our death so that the soul will continue to think, feel, and answer our grandchildren's questions long after our bodies disintegrate. Prof. Tishby of the Interdisciplinary Center for Neural Computation (ICNC) at the Hebrew University of Jerusalem believes that this day is near.
The French-Israeli eye drug maker uses technology developed by the Hebrew University of Jerusalem.
Merck shopping for new technologies for the improvement of drug development
Jerusalem Development Authority allocates initial 10 million NIS to BioJerusalem
Reinventing the wheel- the latest car technology on the Wall Street Journal
A Hebrew University doctoral student who is the first cousin of the president of Chile has won a prestigious research prize for developing a "knockout technique" in special "antibody nose drops" against allergies that he tested successfully on lab mice.
Nava Swersky Sofer isn't the type of person to look back at her accomplishments and congratulate herself. Instead, she says, she's a forward thinker who focuses keenly on her next move.
Tiltan attacks cancer using four different materials
The company has developed a method for applying transgenic tobacco to produce human recombinant collagen.
CBI will purchase 24% of the cancer-drug developer; Yissum keeps its royalties agreement
Novagali Pharma Announces Positive Vekacia(R) Clinical Results from Pivotal Phase III Trial in Vernal Keratoconjunctivitis
Four years after the first information on featherless broiler research was known, the attention of the public and world media was attracted. Commercial trials show the big advantage over their feathered relatives, especially when kept in tropical regions.
Bioline will develop a new drug based on the technology of Prof. Hillel Bercovier and Dr. Ayelet Barenholz of the Hebrew university.
The agreement is reportedly worth several million dollars.